A phase I/IIa trial of docetaxel plus ribavirin for reprogramming efficacy in patients with progressive metastatic castration resistant prostate cancer who have previously received docetaxel alone
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2018
At a glance
- Drugs Ribavirin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms DRREEM
- Sponsors Chugai Pharmaceutical
- 10 Feb 2018 Results (n=6) presented at the 2018 Genitourinary Cancers Symposium.
- 28 Dec 2016 Status changed from recruiting to completed.
- 24 May 2016 New trial record